Nathalie M Bax1, Dyon Valkenburg1, Stanley Lambertus1, B Jeroen Klevering1, Camiel J F Boon2,3, Frank G Holz4, Frans P M Cremers5, Monika Fleckenstein4, Carel B Hoyng1, Moritz Lindner4,6,7. 1. Department of Ophthalmology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 4. Department of Ophthalmology, University of Bonn, Bonn, Germany. 5. Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands. 6. The Nuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom. 7. Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Abstract
Purpose: To describe foveal sparing (FS) in central retinal dystrophies (RD). Methods: Participants for this retrospective study were identified from the retinal dystrophy database of the Department of Ophthalmology at Radboud University Medical Center. FS was defined as an intact foveal structure surrounded by at least 180° of chorioretinal atrophy, and a best-corrected visual acuity (BCVA) of <1.0 logMAR (>20/200 Snellen). Eligible eyes were identified using fundus autofluorescence (FAF) images, and FS was confirmed using near-infrared reflectance (NIR) imaging and spectral-domain optical coherence tomography when available. Clinical and demographic data were extracted from medical records. We performed quantification of FS and chorioretinal atrophic areas using semiautomated software on fundus autofluorescence and NIR images. We calculated the chronologic change using eye-wise linear regression. Results: We identified 36 patients (56 eyes) with FS. RDs included: Stargardt disease (STGD1;20 patients), central areolar choroidal dystrophy (CACD; 7 patients), mitochondrial retinal dystrophy (MRD; 6 patients), pseudo-Stargardt pattern dystrophy (PSPD; 3 patients). Median age at first presentation was 60 (interquartile range [IQR] 54-63) years. Median BCVA at first presentation ranged from 20/25 Snellen in STGD1, to 20/38 Snellen in MRD. Progression of the chorioretinal atrophic area ranged from 0.26 (0.25-0.28) mm/year in PSPD, to 0.14 (0.11-0.22) in CACD. Change in FS area over time was similar between the different dystrophies. Conclusions: The presence of FS in different RDs suggests a disease-independent mechanism that prolongs the survival of the fovea. The associated preservation of BCVA is important for the individual prognosis and has implications for the design of therapeutic trials for RDs.
Purpose: To describe foveal sparing (FS) in central retinal dystrophies (RD). Methods:Participants for this retrospective study were identified from the retinal dystrophy database of the Department of Ophthalmology at Radboud University Medical Center. FS was defined as an intact foveal structure surrounded by at least 180° of chorioretinal atrophy, and a best-corrected visual acuity (BCVA) of <1.0 logMAR (>20/200 Snellen). Eligible eyes were identified using fundus autofluorescence (FAF) images, and FS was confirmed using near-infrared reflectance (NIR) imaging and spectral-domain optical coherence tomography when available. Clinical and demographic data were extracted from medical records. We performed quantification of FS and chorioretinal atrophic areas using semiautomated software on fundus autofluorescence and NIR images. We calculated the chronologic change using eye-wise linear regression. Results: We identified 36 patients (56 eyes) with FS. RDs included: Stargardt disease (STGD1;20 patients), central areolar choroidal dystrophy (CACD; 7 patients), mitochondrial retinal dystrophy (MRD; 6 patients), pseudo-Stargardt pattern dystrophy (PSPD; 3 patients). Median age at first presentation was 60 (interquartile range [IQR] 54-63) years. Median BCVA at first presentation ranged from 20/25 Snellen in STGD1, to 20/38 Snellen in MRD. Progression of the chorioretinal atrophic area ranged from 0.26 (0.25-0.28) mm/year in PSPD, to 0.14 (0.11-0.22) in CACD. Change in FS area over time was similar between the different dystrophies. Conclusions: The presence of FS in different RDs suggests a disease-independent mechanism that prolongs the survival of the fovea. The associated preservation of BCVA is important for the individual prognosis and has implications for the design of therapeutic trials for RDs.
Authors: Liangbo L Shen; Aneesha Ahluwalia; Mengyuan Sun; Benjamin K Young; Holly K Grossetta Nardini; Lucian V Del Priore Journal: Ophthalmol Retina Date: 2020-03-14
Authors: Tjaša Krašovec; Marija Volk; Maja Šuštar Habjan; Marko Hawlina; Nataša Vidović Valentinčič; Ana Fakin Journal: Int J Mol Sci Date: 2022-07-02 Impact factor: 6.208
Authors: João Paulo Kazmierczak de Camargo; Giovanna Nazaré de Barros Prezia; Naoye Shiokawa; Mario Teruo Sato; Roberto Rosati; Angelica Beate Winter Boldt Journal: Front Genet Date: 2022-05-17 Impact factor: 4.772
Authors: Xiangrong Kong; Mohamed Ibrahim-Ahmed; Millena G Bittencourt; Rupert W Strauss; David G Birch; Artur V Cideciyan; Ann-Margaret Ervin; Alexander Ho; Janet S Sunness; Isabelle S Audo; Michel Michaelides; Eberhart Zrenner; SriniVas Sadda; Michael S Ip; Sheila West; Hendrik P N Scholl Journal: Am J Ophthalmol Date: 2021-10-23 Impact factor: 5.258